Join
Live feed
·
PRReleasevia Quantisnow
KemPharm Inc. logo

KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy

ByQuantisnow·Wall Street's wire, on your screen.
KMPH· KemPharm Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KMPH (KemPharm Inc.) and more on Quantisnow.